Related Experiment Videos
[Radiotherapy for pancreatic cancer]
Eduardo Weltman1, Joao Victor Salvajoli, Rodrigo de Morais Hanriot
1Serviço de Radioterapia, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil. eweltman@einstein.br
Revista Da Associacao Medica Brasileira (1992)
|September 3, 2002
Summary
Pancreatic adenocarcinoma treatment shows modest survival gains with radiotherapy and chemotherapy. Further improvements require novel drugs and intraoperative radiotherapy for better patient outcomes.
Area of Science:
- Oncology
- Radiation Oncology
Context:
- Pancreatic adenocarcinoma is an aggressive malignancy with poor prognosis.
- Current adjuvant therapies offer limited survival benefits.
Purpose:
- To evaluate the survival outcomes of pancreatic adenocarcinoma patients treated with radiotherapy.
Summary:
- Retrospective analysis of 40 patients undergoing radical surgery or palliative procedures.
- Median survival was 14.8 months; 1- and 2-year survival rates were 70% and 22.2% respectively.
- Resected tumors showed improved survival (21.4 months median) compared to non-resected (16.1 months median).
Impact:
- Findings align with existing literature, highlighting the need for improved treatment strategies.
- Suggests a need for better chemotherapeutic agents and increased use of intraoperative radiotherapy.